From the American Academy of Ophthalmology

The U.S. Food and Drug Administration has approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema. The drug’s safety and effectiveness to treat DME were established in two clinical studies that showed a 34 to 45 percent improvement in patients treated monthly with 0.3 mg of Lucentis over a two-year period. Ophthalmologists should check with their Medicare carriers to determine coverage for Lucentis to treat DME.

From the American Academy of Ophthalmology

From the American Academy of Ophthalmology

From the American Academy of Ophthalmology

Physicians have an additional year, until Oct. 14, 2014, to transition from the ICD-9 coding system to ICD-10. The U.S. Department of Health and Human Services is delaying the mandatory transition in part because of the number of federal compliance burdens that physician practices face, including requirements of the Medicare electronic health record incentive program and upcoming penalties for not participating in the Physician Quality Reporting System.